Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy
<b>Conclusions:</b> This case identifies distinct histopathological features in ixekizumab-induced DI-ILD, particularly the presence of granulomatous changes and Th17 cell involvement. The findings suggest that IL-17A inhibition may trigger pulmonary inflammation through Th17 cell function dysregulation. This observation supports the importance of careful pulmonary monitoring in patients receiving biologic therapies for psoriasis, particularly those with pre-existing lung conditions. TBLC may contribute to understanding the pathogenesis of this drug-induced complication.
Authors
- Kazuo Kasahara (ORCID: https://orcid.org/0000-0001-5551-1543)
- Koichiro Kamio (ORCID: https://orcid.org/0000-0002-6870-9548)
- Shota Kaburaki (ORCID: https://orcid.org/0000-0002-1194-087X)
- Masahiro Seike (ORCID: https://orcid.org/0000-0002-1572-5472)
- Yasuhiro Terasaki (ORCID: https://orcid.org/0000-0003-4495-7982)
- Toru Tanaka (ORCID: https://orcid.org/0000-0002-2958-2548)
- Yosuke Tanaka (ORCID: https://orcid.org/0000-0002-3290-2848)
- Naoko Okada
Institutions
- Nippon Medical School (JP)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2024-11-10
- DOI
- https://doi.org/10.1080/09546634.2024.2424338
- Citations
- 3
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 1.26